Global Mission

Sickle cell disease (SCD) is a global problem. As the most common genetic disease in the world, SCD touches the lives of millions and affects many more. People of at least five racial groups and numerous ethnic origins have inherited the sickle gene. SCD is correctly classified as a “tropical disease”, since it is most common among populations living close to the equator, in tropical and subtropical regions. The populations in which SCD occurs most frequently live in Africa (which has about 75% of the cases), in Mediterranean countries, in the Middle East, and in India, with significant numbers in the Caribbean, Brazil, and Oceania. Migrations of people from these regions have resulted in significant numbers of SCD suffers in North America, South America, and Europe. The prevalence and continued high incidence of sickle cell is due in large part to resistance to the chronic effects of malaria that is conferred by the presence of sickle hemoglobin in the red blood cells of carriers, as well as SCD patients fortunate enough to survive childhood. However, this benefit of the sickle trait comes at a very high cost to those who inherit two copies of the sickle gene. SCD is a terrible disease that brings with it pain that is frequent and often severe, life-threatening organ damage, and limitations to the daily lives of the sufferers and their families. In developing countries short on comprehensive medical care, SCD is a death sentence that terminates life early, often within the first two years.

SCCF has a cure that prevents manifestations of the bodily damage which results from SCD! Our cure is the product of 33 years of research funded by NIH and other non-profit foundations. This cure is truly unique, very stable, easy to deliver, and has very low likelihood of side effects. The effectiveness has been proven in more than 50 types of laboratory experiments, each repeated multiple times by different investigators.

The SCCF is committed to alleviating this terrible disease in as many suffers as can be reached. To this end, the SCCF has a global plan for distribution of the cure at a cost that 80% of the SCD sufferers in the world can afford. Our plan combines safety and clinical trials with a cost-effective business plan that includes a “north-south” dialogue and “west-east” cross subsidies from advanced economies to economically less affluent regions in such a way that all people may receive the “cure” at a cost much lower than what they now incur for inferior, much less effective treatments. This global plan has SCCF partnering with other charities to create teams with the management skills, medical knowledge, multi-cultural experience, timely funding, and – above all — passionate commitment, as well as the experience on the ground to deliver this long-awaited cure to humanity. How Oklahoma came to be the discovery location for a tropical disease is a story in its own right composed of new facts, sound growth policies, and the occasional stroke of genius. Oklahoma’s pro-business policies certainly favor economic development of the bio-medical sector. Insights into evolutionary and developmental biology influenced how to structure the “search”. Discoveries in basic science rarely unfold on schedule, within budget, with no detours. In a field as creative as biomedical research, there will always be the “unknown” where insight and intuition merge.